Agranulocytosis, acquired
The VA rates Agranulocytosis, acquired under Diagnostic Code 7702 across 4 severity levels, from 10% to 100%. At 100%, veterans receive $3939/month or more in compensation.
Rating schedule — DC 7702 at a glance
- Minimum rating
- 10%
- Maximum rating
- 100%
- Rating tiers
- 4
- CFR section
- § 4.117
- Body system
- Hematologic & Lymphatic System
- Secondary conditions
- 0
Lowest schedular rating available
Full schedular disability
10%, 30%, 60%, 100%
Part 4 rating schedule
None mapped
What are the VA rating criteria for Agranulocytosis, acquired?
| Rating | Criteria |
|---|---|
| 10% | Requiring continuous medication (e.g., antibiotics) for control; or requiring intermittent use of a myeloid growth factor to maintain ANC greater than or equal to 1500/µl |
| 30% | Requiring intermittent myeloid growth factors to maintain ANC greater than 1000/µl; or infections recurring, on average, at least once per 12-month period but less than once every three months per 12-month period |
| 60% | Requiring intermittent myeloid growth factors (granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or continuous immunosuppressive therapy such as cyclosporine to maintain absolute neutrophil count (ANC) greater than 500/microliter (µl) but less than 1000/µl; or infections recurring, on average, at least once every three months per 12-month period |
| 100% | Requiring bone marrow transplant; or infections recurring, on average, at least once every six weeks per 12-month period |
“Requiring intermittent myeloid growth factors (granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) or continuous immunosuppressive therapy such as cyclosporine to maintain absolute neutrophil count (ANC) greater than 500/microliter (µl) but less than 1000/µl; or infections recurring, on average, at least once every three months per 12-month period”
Common Questions About Agranulocytosis, acquired VA Ratings
What is the VA rating range for Agranulocytosis, acquired?
The VA rates Agranulocytosis, acquired under Diagnostic Code 7702 at 10%, 30%, 60%, 100%. The minimum 10% rating requires: Requiring continuous medication (e.g., antibiotics) for control; or requiring intermittent use of a myeloid growth factor to maintain ANC greater than or equal to 1500/µl. The maximum 100% rating requires: Requiring bone marrow transplant; or infections recurring, on average, at least once every six weeks per 12-month period.
Which 38 CFR diagnostic code does the VA use for Agranulocytosis, acquired?
The VA rates Agranulocytosis, acquired under Diagnostic Code (DC) 7702, governed by 38 CFR 38 CFR § 4.117. The diagnostic code establishes the specific rating tiers and severity criteria the VA examiner applies.
What is the difference between a 10% and a 100% rating for Agranulocytosis, acquired?
A 10% rating requires: Requiring continuous medication (e.g., antibiotics) for control; or requiring intermittent use of a myeloid growth factor to maintain ANC greater than or equal to 1500/µl. A 100% rating requires: Requiring bone marrow transplant; or infections recurring, on average, at least once every six weeks per 12-month period. The difference typically reflects the frequency, severity, or functional impact of the condition as documented in medical records and C&P examination findings.
Can Agranulocytosis, acquired qualify for TDIU?
Yes — a 100% rating for Agranulocytosis, acquired alone meets the single-disability threshold for TDIU (38 CFR § 4.16). If the condition prevents substantially gainful employment, the veteran is compensated at the 100% rate without a schedular 100% rating.
What evidence supports a higher rating for Agranulocytosis, acquired?
The key evidence for Agranulocytosis, acquired is documentation of how the condition affects daily functioning. Treatment records showing worsening symptoms, functional limitations documented by your provider, and buddy statements describing observable impact on daily life all strengthen the claim. A nexus letter from a qualified medical professional linking the current severity to service is essential for contested claims.
What happens at the C&P exam for Agranulocytosis, acquired?
The C&P examiner uses a Hematologic & Lymphatic System DBQ and evaluates your condition against the DC 7702 rating criteria. The examiner documents symptom frequency, severity, and functional impact. Bring all treatment records and describe your worst days, not your best — the VA rates on the full clinical picture across time, not a snapshot of one good day.
Get a Personalized Rating Analysis
VeteranHQ evaluates your symptoms against the exact 38 CFR criteria, identifies secondary conditions, and shows what evidence you need to support a higher rating.
Discover Your Benefits